IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (??) T cell therapies for cancer and autoimmune diseases, has announced upcoming presentations by CEO William Ho at two notable conferences in February 2026. The first conference, the Noble Emerging Growth Virtual Equity Conference, will take place on February 5 at 3:00 p.m. ET. This virtual event aims to connect emerging growth companies with investors. The second conference, the IO360° Conference, is scheduled for February 12, during which Ho will present from 1:20 p.m. to 1:40 p.m. ET. His session will focus on the “IO Clinical Advancements Plenary,” showcasing IN8bio's distinctive DeltEx Drug Resistant Immunotherapy (DRI) approach and preliminary results from a Phase 1/2 study examining this treatment for newly diagnosed glioblastoma (GBM).

IN8bio is at the forefront of addressing unmet medical needs with its innovative product candidates targeting various malignancies and autoimmune conditions. Its lead program, INB-100, involves the application of haplo-matched allogeneic ?? T cells administered to patients following hematopoietic stem cell transplants aimed at treating acute myeloid leukemia. Additionally, the company is exploring autologous DeltEx DRI ?? T cells combined with standard therapies for glioblastoma in its INB-200 and INB-400 programs. Furthermore, IN8bio is progressing its INB-600 program, which focuses on the development of novel ?? T cell engagers intended for diverse oncology and autoimmune indications.

For more details about IN8bio, including access to conference webcasts, investors and interested parties are encouraged to visit the company’s website at www.in8bio.com.

As IN8bio, Inc. (Nasdaq: INAB) gears up for its February presentations at prestigious investor and scientific conferences, market watchers should consider a strategic approach to this clinical-stage biopharmaceutical company, particularly with its focus on innovative gamma-delta T cell therapies.

The upcoming conferences, including the Noble Emerging Growth Virtual Equity Conference and the IO360° Conference, represent a critical opportunity for IN8bio to showcase its leading-edge research and establish a stronger foothold in the biotech sector. The presentations will shed more light on IN8bio's unique DeltEx Drug Resistant Immunotherapy (DRI) approach to treating solid tumors and recent clinical findings from its studies on newly diagnosed glioblastoma multiforme (GBM). This therapeutic focus could make IN8bio a key player in addressing significant unmet medical needs, particularly given the challenging nature of GBM and acute myeloid leukemia.

Investors should pay close attention to the clinical data that will be discussed at these conferences. Positive data could act as a catalyst for stock price appreciation as it can validate the company's innovative therapies and bolster investor confidence. Conversely, any negative or inconclusive results could detract from market enthusiasm and lead to volatility.

Furthermore, with ongoing advancements in oncology and the increasing importance of targeted therapies, IN8bio's focus on haplo-matched and autologous T cell therapies aligns well with global trends in personalized medicine. As the market increasingly favors companies positioned to deliver cutting-edge treatments, IN8bio's valuation could benefit from the sustained interest in immunotherapy.

In summary, investors should closely monitor the outcomes of IN8bio's conference presentations. A positive reception could initiate a bullish trend, whereas caution is advised if the data does not meet market expectations. As always, balancing potential risks with the promising future of the company's therapies is crucial.